Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks

The 144-week results of the open-label, multicenter Atazanavir/Ritonavir Induction with Epzicom Study (ARIES) were stratified by gender to compare treatment responses. A total of 369 HIV-infected, antiretroviral-naïve subjects receiving once-daily abacavir/lamivudine + atazanavir/ritonavir (ATV/r) w...

Full description

Saved in:
Bibliographic Details
Published in:HIV/AIDS (Auckland) 2017-01, Vol.9, p.51-61
Main Authors: Squires, Kathleen E, Young, Benjamin, Santiago, Lizette, Dretler, Robin H, Walmsley, Sharon L, Zhao, Henry H, Pakes, Gary E, Ross, Lisa L, Shaefer, Mark S
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
AIDS
Analysis
Antiretroviral agents
Antiretroviral drugs
Antiviral drugs
ARIES
Dosage and administration
Drug therapy
HIV
HIV infections
HIV-infected
Human immunodeficiency virus
Original Research
Patient compliance
Risk factors
sex
virologic efficacy
Womens health
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The 144-week results of the open-label, multicenter Atazanavir/Ritonavir Induction with Epzicom Study (ARIES) were stratified by gender to compare treatment responses. A total of 369 HIV-infected, antiretroviral-naïve subjects receiving once-daily abacavir/lamivudine + atazanavir/ritonavir (ATV/r) whose HIV-1 RNA was
ISSN:1179-1373
1179-1373
DOI:10.2147/HIV.S108756